Wyeth, Elan halt study of Alzheimer's vaccine

Share this article:
Wyeth and Elan have suspended a clinical study of their jointly developed Alzheimer's vaccine ACC-001 after a patient receiving the treatment was hospitalized for nearly two weeks with skin ulcers.

The patient developed the skin ulcers on March 6 and Wyeth reported the findings to the FDA on March 20.

The agency asked the companies to halt the trials April 4, Wyeth spokesman Michael Lampe told Bloomberg News.

“The FDA can delay the start of a study or request no further dosing take place until the issues raised have been addressed,” Lampe said. “If they are addressed to the satisfaction of the agency, the hold can be lifted. Additional information is being gathered and will be shared with the agency.”

The patient was reported to be recovering from the skin lesions, however it remains unclear how many doses the patient received.

Analysts have forecast that the treatment could generate more than $5 billion in annual sales.
Wyeth is reported to have more than 350 scientists working on Alzheimer's treatments and has spent more than $500 million on the disease since 2001. Meanwhile, half of Elan's $335 million annual budget for research and development goes toward Alzheimer's.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.